Precision Medicine News and Updates | Precision Medicine Online
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026. Immatics Moving PRAME-Directed Autologous TCR T-Cell Melanoma Therapy to Phase III. The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after ...
Precision Oncology News - Precision Medicine Online
Oct 14, 2024 · Burning Rock, Dizal Get Chinese Approval for Lung Cancer CDx. Oct 11, 2024. USC Team Counts Circulating Tumor Cells to Predict Treatment Response, Survival in Prostate Cancer. Load More. The latest news on companion diagnostics and personalized cancer therapy from Precision Medicine Online.
Breaking News - Precision Medicine Online
6 days ago · UK's NICE Recommends Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer. The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients. Oct 16, 2024.
Clinical Sequencing News | Precision Medicine Online
Jul 29, 2024 · News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics. from Precision Medicine Online.
Disease Research & Diagnostics News | Precision Medicine Online
News and analysis on disease research and diagnostics from Precision Medicine Online.
Precision Oncology in 2022: New Drugs and Tests Amid Ongoing …
Jan 4, 2023 · NEW YORK – Looking back at 2022, plenty of new CAR T-cell, radioligand, and biomarker-defined treatments entered the market, as did new tissue and liquid biopsy tests to identify cancer patients eligible for these therapies.
NIH Precision Oncology News | Precision Medicine Online
News and reporting on NIH from Precision Medicine Online Precision Oncology
Genomics Technology, Tools & Methods - Precision Medicine Online
Oct 2, 2024 · The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. The test, approved by Chinese regulators in early 2022, is designed for the detection of multiple mutation statuses for nine genes. The ...
Disease Research for Precision Medicine | Precision Medicine Online
Sep 19, 2024 · Janssen Pharma to Make CHF 24.6M Milestone Payment to AC Immune Tied to Anti-Tau Alzheimer's Trial. Sep 17, 2024. Intellia Therapeutics Testing Gene Insertion Therapy for AATD-Linked Lung Disease. Sep 17, 2024. Natera Links ctDNA Status to Overall Survival, Therapy Response in GALAXY Study Update. Sep 16, 2024.
Precision Oncology Precision Oncology News - Precision Medicine …
Oct 7, 2024 · The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.